Pooled analysis of the prognostic and predictive effects of KRAS mutation status and KRAS mutation subtype in early-stage resected non-small-cell lung cancer in four trials of adjuvant chemotherapy.
about
Integrating the molecular background of targeted therapy and immunotherapy in lung cancer: a way to explore the impact of mutational landscape on tumor immunogenicityPromising Targets and Current Clinical Trials in Metastatic Non-Squamous NSCLCCo-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities.KRAS-driven lung adenocarcinoma: combined DDR1/Notch inhibition as an effective therapyTargeted Therapies in Non-Small Cell Lung Cancer-Beyond EGFR and ALKGenomic profiling toward precision medicine in non-small cell lung cancer: getting beyond EGFRLung Cancer Gene Signatures and Clinical PerspectivesLipophilic bisphosphonates plus rapamycin: a deadly combination for KRAS-mutated lung adenocarcinomaRationale for RAS mutation-tailored therapies.Clinicopathological and prognostic features of surgically resected pathological stage I lung adenocarcinoma harboring epidermal growth factor receptor and K-ras mutation.Prognostic value of tumor mutations in radically treated locally advanced non-small cell lung cancer patients.Adjuvant chemotherapy of non-small-cell lung cancer.Diagnostic and prognostic value of blood samples for KRAS mutation identification in lung cancer: a meta-analysis.Noninvasive image texture analysis differentiates K-ras mutation from pan-wildtype NSCLC and is prognostic.Biomarkers That Currently Affect Clinical Practice in Lung Cancer: EGFR, ALK, MET, ROS-1, and KRASTargeted therapies in non-small cell lung cancer: emerging oncogene targets following the success of epidermal growth factor receptor.Novel agents in development for advanced non-small cell lung cancer.Biomarkers in early-stage non-small-cell lung cancer: current concepts and future directions.Molecularly targeted therapies in non-small-cell lung cancer annual update 2014Prognostic markers in lung cancer: is it ready for prime time?Outcomes by tumor histology and KRAS mutation status after lung stereotactic body radiation therapy for early-stage non-small-cell lung cancer.Epidermal growth factor receptor variant III mutation in Chinese patients with squamous cell cancer of the lungPrognostic impact of KRAS mutation subtypes in 677 patients with metastatic lung adenocarcinomasCharacterization of 1577 primary prostate cancers reveals novel biological and clinicopathologic insights into molecular subtypes.Subtype Classification of Lung Adenocarcinoma Predicts Benefit From Adjuvant Chemotherapy in Patients Undergoing Complete Resection.Impact of KRAS mutation on response and outcome of patients with stage III non-squamous non-small cell lung cancerKRAS mutant lung cancer: progress thus far on an elusive therapeutic target.Elderly male smokers with right lung tumors are viable candidates for KRAS mutation screening.Clinical outcome of epidermal growth factor receptor-tyrosine kinase inhibitors therapy for patients with overlapping kirsten rat sarcoma 2 viral oncogene homolog and epidermal growth factor receptor gene mutationsKRAS mutations affect prognosis of non-small-cell lung cancer patients treated with first-line platinum containing chemotherapySurvival outcome according to KRAS mutation status in newly diagnosed patients with stage IV non-small cell lung cancer treated with platinum doublet chemotherapy.Analysis of KRAS and BRAF genes mutation in the central nervous system metastases of non-small cell lung cancerDiscordance of Mutation Statuses of Epidermal Growth Factor Receptor and K-ras between Primary Adenocarcinoma of Lung and Brain MetastasisKRAS mutation is a weak, but valid predictor for poor prognosis and treatment outcomes in NSCLC: A meta-analysis of 41 studies.KRAS Mutation in Small Cell Lung Carcinoma and Extrapulmonary Small Cell Cancer.Analysis of the frequency of EGFR, KRAS and ALK mutations in patients with lung adenocarcinoma in Croatia.Identification of a KRAS mutation in a patient with non-small cell lung cancer treated with chemoradiotherapy and panitumumab.Circulating and tissue biomarkers in early-stage non-small cell lung cancerMolecular markers to predict clinical outcome and radiation induced toxicity in lung cancerMEK inhibition in non-small cell lung cancer.
P2860
Q26769744-B79ADDB4-2E21-4013-92EA-50B590CC408FQ27025970-99E5FA13-C6D7-4719-96D1-DB47FAD9E3D5Q27345462-21296F16-F33D-427F-ADFC-FD6A1E1C0F1CQ28069764-5E7D1327-6197-4A92-B944-26D291AF6A59Q28083446-8E901968-B23A-47B8-B42C-2A2CD13926A1Q28086993-7C008F0B-8706-401B-957E-A877EC8F9A68Q28387769-E8B18A49-9607-42CE-94AB-82ED38303AF3Q28606634-ACB346EE-AB42-4468-9E41-E60471F4F1ACQ30244673-D8EA6E9C-8117-4F6C-8911-076D5FAB4E7FQ33633715-1C833F45-A8B9-4FAD-A587-0A1CAB68F25AQ33648808-D8D502E4-7733-496D-B8F4-63CCFF773327Q33698361-820C1F19-2F9F-4687-A162-3DD0216B5E06Q33829668-E0E7117C-957D-41DA-8A4D-5BDE2185F6C9Q33836797-B4E14697-48F5-42F2-AAB0-F7CA424507FFQ34023414-1ED531D9-963E-4186-8BC7-201030B5BEDFQ34158153-07F18C59-AEF9-46D1-A675-0D78ED1BCA73Q34389263-EF52FF94-1D12-4909-A79A-DC61A065F97CQ34623884-D0AF295E-81D6-4C18-80B9-3FCC3B9F2F15Q35136424-EA116771-1033-4EED-8B0A-F24FAC9D7868Q35200555-8FE37E66-70BD-4277-BDD4-814F06E74EA7Q35592628-7F654658-F511-443C-928A-190516F15533Q35663430-A73278F7-DF62-4811-9A48-2AEA57D81D95Q35775729-BC909E9F-66A9-4DAB-9195-B933EE428962Q36035812-11A554D3-F210-48E2-88E1-7AE8F63E94B5Q36162509-8B85FBB2-55F8-409F-89DC-95F5681081E3Q36262860-7C745683-CEB9-42D2-B255-CFACFE408DFFQ36369197-722D19D5-FE37-4521-AA9F-A1DF1037BE0FQ36438421-ECE3E193-F639-4909-8906-13D021F7A416Q36477762-BE819588-9E27-4ACA-8C7D-C7BCB4DA27CCQ36545375-BFBF6D1D-0512-48E3-AC84-A22DC6B01CAFQ36557569-AEEEB63A-5914-41C6-AFFB-E173021C09A3Q36834504-DE4D8617-2102-434E-B7CD-A9AEA729C674Q36847104-420F9AF3-01C2-4702-A56C-861897D8354DQ36946809-6F1F6033-28DA-4275-B6DC-D620FB0B7844Q37211434-57CD61A7-531C-42FF-8FDE-1385FB45F1B5Q37272817-FC7D9631-FDEC-4541-8AD5-954F74090454Q37589223-DC96C549-5E75-4DE5-A9E7-0B0EB2F1FC2FQ37629653-EDE62B61-062B-44B0-9BEF-BD3BE2DA01ECQ37670436-1C033B34-0C7E-423D-8B06-BD487DC66E52Q38254501-B5E61167-F7EB-45E9-B4B9-192D88EA82B7
P2860
Pooled analysis of the prognostic and predictive effects of KRAS mutation status and KRAS mutation subtype in early-stage resected non-small-cell lung cancer in four trials of adjuvant chemotherapy.
description
2013 nî lūn-bûn
@nan
2013 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Pooled Analysis of the Prognos ...... rials of Adjuvant Chemotherapy
@nl
Pooled analysis of the prognos ...... ials of adjuvant chemotherapy.
@ast
Pooled analysis of the prognos ...... ials of adjuvant chemotherapy.
@en
type
label
Pooled Analysis of the Prognos ...... rials of Adjuvant Chemotherapy
@nl
Pooled analysis of the prognos ...... ials of adjuvant chemotherapy.
@ast
Pooled analysis of the prognos ...... ials of adjuvant chemotherapy.
@en
prefLabel
Pooled Analysis of the Prognos ...... rials of Adjuvant Chemotherapy
@nl
Pooled analysis of the prognos ...... ials of adjuvant chemotherapy.
@ast
Pooled analysis of the prognos ...... ials of adjuvant chemotherapy.
@en
P2093
P2860
P50
P3181
P356
P1476
Pooled analysis of the prognos ...... ials of adjuvant chemotherapy.
@en
P2093
Abderrahmane Bourredjem
Bizhan Bandarchi
Caroline Domerg
Elizabeth Brambilla
Frances A Shepherd
Lesley Seymour
Martin Filipits
Robert Kratzke
Robert Pirker
Stephen Graziano
P2860
P304
P3181
P356
10.1200/JCO.2012.48.1390
P407
P50
P577
2013-04-29T00:00:00Z